Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
Xin He,1,2 Dongyue Yang,1,2 Lingyao Lai,1,2 Jing Lang,1,2 Kebo Wei,1,2 Min Xiao1 1Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People’s Republic of China; 2School of Clinical Medicine, Chengdu University of Traditional Chinese...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2024-03-01
|
| Series: | Clinical, Cosmetic and Investigational Dermatology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/upadacitinib-for-alopecia-areata-in-different-backgrounds-a-case-serie-peer-reviewed-fulltext-article-CCID |
| _version_ | 1797266491431714816 |
|---|---|
| author | He X Yang D Lai L Lang J Wei K Xiao M |
| author_facet | He X Yang D Lai L Lang J Wei K Xiao M |
| author_sort | He X |
| collection | DOAJ |
| description | Xin He,1,2 Dongyue Yang,1,2 Lingyao Lai,1,2 Jing Lang,1,2 Kebo Wei,1,2 Min Xiao1 1Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People’s Republic of China; 2School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People’s Republic of ChinaCorrespondence: Min Xiao, Email xiaomin@cdutcm.edu.cnAbstract: Alopecia Areata is a hair disorder influenced by factors such as genetics, immune system, and environmental triggers. The pathogenesis of this condition is still unclear, leading to unsatisfactory current treatments and causing a large number of patients to suffer from it. Janus kinase inhibitors are a new class of drugs that have emerged in recent years and are expected to be promising therapeutic tools for alopecia areata. We report five patients with varying backgrounds and severity of alopecia areata. All of them had received conventional therapy without success. Five patients took Upadacitinib at a dose of 15 mg once daily, and all of them achieved satisfactory efficacy. No adverse events were observed during the treatment of 5 patients.Keywords: upadacitinib, alopecia areata, JAK inhibitors, JAK-STAT |
| first_indexed | 2024-04-25T01:01:32Z |
| format | Article |
| id | doaj.art-59b796d5d949434fb9010016a5b60ac2 |
| institution | Directory Open Access Journal |
| issn | 1178-7015 |
| language | English |
| last_indexed | 2024-04-25T01:01:32Z |
| publishDate | 2024-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical, Cosmetic and Investigational Dermatology |
| spelling | doaj.art-59b796d5d949434fb9010016a5b60ac22024-03-10T16:38:19ZengDove Medical PressClinical, Cosmetic and Investigational Dermatology1178-70152024-03-01Volume 1756557191098Upadacitinib for Alopecia Areata in Different Backgrounds: A Case SeriesHe XYang DLai LLang JWei KXiao MXin He,1,2 Dongyue Yang,1,2 Lingyao Lai,1,2 Jing Lang,1,2 Kebo Wei,1,2 Min Xiao1 1Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People’s Republic of China; 2School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People’s Republic of ChinaCorrespondence: Min Xiao, Email xiaomin@cdutcm.edu.cnAbstract: Alopecia Areata is a hair disorder influenced by factors such as genetics, immune system, and environmental triggers. The pathogenesis of this condition is still unclear, leading to unsatisfactory current treatments and causing a large number of patients to suffer from it. Janus kinase inhibitors are a new class of drugs that have emerged in recent years and are expected to be promising therapeutic tools for alopecia areata. We report five patients with varying backgrounds and severity of alopecia areata. All of them had received conventional therapy without success. Five patients took Upadacitinib at a dose of 15 mg once daily, and all of them achieved satisfactory efficacy. No adverse events were observed during the treatment of 5 patients.Keywords: upadacitinib, alopecia areata, JAK inhibitors, JAK-STAThttps://www.dovepress.com/upadacitinib-for-alopecia-areata-in-different-backgrounds-a-case-serie-peer-reviewed-fulltext-article-CCIDupadacitinibalopecia areatajak inhibitorsjak-stat |
| spellingShingle | He X Yang D Lai L Lang J Wei K Xiao M Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series Clinical, Cosmetic and Investigational Dermatology upadacitinib alopecia areata jak inhibitors jak-stat |
| title | Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series |
| title_full | Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series |
| title_fullStr | Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series |
| title_full_unstemmed | Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series |
| title_short | Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series |
| title_sort | upadacitinib for alopecia areata in different backgrounds a case series |
| topic | upadacitinib alopecia areata jak inhibitors jak-stat |
| url | https://www.dovepress.com/upadacitinib-for-alopecia-areata-in-different-backgrounds-a-case-serie-peer-reviewed-fulltext-article-CCID |
| work_keys_str_mv | AT hex upadacitinibforalopeciaareataindifferentbackgroundsacaseseries AT yangd upadacitinibforalopeciaareataindifferentbackgroundsacaseseries AT lail upadacitinibforalopeciaareataindifferentbackgroundsacaseseries AT langj upadacitinibforalopeciaareataindifferentbackgroundsacaseseries AT weik upadacitinibforalopeciaareataindifferentbackgroundsacaseseries AT xiaom upadacitinibforalopeciaareataindifferentbackgroundsacaseseries |